Introduction to PLGA CNS Drug Delivery Blood-Brain Barrier Systems
PLGA CNS Drug Delivery Blood-Brain Barrier systems are advanced polymeric nanocarriers designed to transport therapeutic agents across the highly restrictive blood-brain barrier (BBB) for the treatment of neurological disorders. By utilizing biodegradable poly(lactic-co-glycolic acid) (PLGA), these systems protect sensitive drug molecules, improve stability, and enhance delivery to the central nervous system (CNS).
The treatment of CNS disorders such as glioblastoma multiforme (GBM), Alzheimer’s disease, Parkinson’s disease, and ischemic stroke remains challenging due to the BBB. This specialized barrier is formed by brain capillary endothelial cells connected by tight junctions and supported by pericytes, astrocytes, and a basement membrane. As a result, more than 98% of small-molecule drugs and nearly all large-molecule therapeutics, including proteins, peptides, DNA, and RNA-based therapies, are unable to reach the brain effectively.
Even when certain lipophilic drugs cross the BBB, active efflux transporters such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins (MRPs) can rapidly remove them from the brain. To overcome these challenges, PLGA nanoparticles have emerged as one of the most promising drug delivery platforms.
PLGA is a biocompatible and biodegradable copolymer approved by both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for parenteral applications. Following administration, PLGA degrades into lactic acid and glycolic acid, which are naturally metabolized through the citric acid (Krebs) cycle. Additionally, its degradation rate and drug release profile can be precisely controlled by adjusting the lactic-to-glycolic acid ratio, molecular weight, and end-group chemistry, enabling sustained therapeutic delivery ranging from weeks to several months.
Explore the essential differences in performance and application between PLGA and other polymers: Understand PLA vs. PLGA vs. PCL properties
Article Summary:
- PLGA nanoparticles are promising carriers for brain drug delivery, helping therapeutic molecules cross the highly selective blood-brain barrier (BBB) and improving treatment potential for neurological disorders such as glioblastoma, Alzheimer’s disease, Parkinson’s disease, and stroke.
- The BBB prevents most medicines from reaching the brain, blocking the vast majority of small-molecule drugs and nearly all large biological therapeutics. In addition, efflux transporters actively remove many drugs that do enter brain tissue.
- PLGA is widely used because it is biodegradable, biocompatible, and clinically accepted. After administration, it breaks down into naturally metabolized compounds, while its composition can be tailored to achieve controlled and sustained drug release.
- First-generation PLGA nanocarriers focus on circulation enhancement. Researchers optimize particle size (typically 100–150 nm) and apply hydrophilic surface coatings such as PEG to reduce immune recognition, prolong bloodstream residence time, and improve opportunities for BBB interaction.
- Advanced stealth technologies are being developed to overcome PEG-related limitations. Alternatives such as highly branched polyglycerol (HPG) can extend circulation time while reducing the risk of immune responses associated with repeated PEG exposure.
- Second-generation PLGA systems use active targeting mechanisms by attaching ligands, surfactants, proteins, or peptides that trigger receptor-mediated transport across brain endothelial cells. Examples include Polysorbate 80, Angiopep-2, transferrin, lactoferrin, and cell-penetrating peptides.
- Emerging strategies combine multiple targeting approaches to further improve brain delivery. Techniques such as transporter-mediated transport, adsorptive-mediated transcytosis, phage display-derived targeting peptides, and focused ultrasound-assisted delivery are expanding the potential of PLGA nanocarriers for precise and effective CNS therapy, although rigorous quality control and clinical validation remain essential for successful translation.
Pre-Transcytosis Engineering: Size Optimization and Hydrophilic Stealth Modification
First-generation PLGA nanoparticles achieve passive stabilization within the bloodstream through meticulous control of particle size and surface modification using hydrophilic polymers such as PEG or poloxamers. These modifications help evade recognition and clearance by the reticuloendothelial system, thereby prolonging circulation time and increasing the likelihood of interaction with the brain capillary endothelium.
Native PLGA nanoparticles typically possess a negative surface charge, with zeta potentials generally ranging from -15 mV to -25 mV, and exhibit a hydrophobic outer surface. Following intravenous administration, this hydrophobic surface rapidly undergoes opsonization, during which plasma proteins adsorb onto the nanoparticle surface. These opsonized particles are then recognized by scavenger receptors present on macrophages within the liver (Kupffer cells) and spleen, resulting in rapid systemic clearance. Consequently, unmodified PLGA formulations exhibit limited circulation times, with less than 1% of the administered dose ultimately reaching the brain.
To address these pre-transcytosis challenges and improve circulation kinetics, researchers commonly employ two primary engineering strategies:
Strict Size Control
Nanoparticles are engineered to possess a uniform hydrodynamic diameter between 100 and 150 nm. This carefully selected size range prevents rapid renal filtration (<10 nm) while also minimizing mechanical sequestration and clearance within the splenic red pulp (>200 nm). Maintaining nanoparticles within this optimal size window ensures prolonged circulation and increased opportunities for BBB interaction.
Ensure your formulation meets stringent standards: Learn about PLGA polymer molecular weight and PDI control
Hydrophilic Stealth Shielding (PEGylation)
Hydrophilic polymers, particularly poly(ethylene glycol) (PEG), are covalently attached to the terminal end-groups of PLGA to generate diblock (PEG-b-PLGA) or triblock (PLGA-b-PEG-b-PLGA) copolymers. These block copolymers self-assemble into core-shell structures in which the hydrophobic PLGA core encapsulates the therapeutic cargo, while the hydrophilic PEG chains extend outward to form a protective hydration layer.
This hydrated shell provides steric stabilization by repelling plasma proteins and opsonins, significantly reducing reticuloendothelial uptake and extending systemic circulation half-life.
Optimize your particles for better performance: Master PLGA PDI in pharmaceutical applications
Although PEGylation has long been considered the clinical standard for stealth nanocarriers, repeated administration of PEGylated formulations can induce anti-PEG immunological responses. The production of anti-PEG IgM antibodies may trigger accelerated blood clearance (ABC) upon subsequent dosing, thereby reducing therapeutic effectiveness.
To overcome this limitation, researchers are developing PEG-free stealth alternatives. One promising strategy involves coating PLGA nanoparticles with highly branched polyglycerol (HPG), which forms a hydrophilic, unstructured shell capable of providing prolonged circulation while avoiding anti-PEG immune responses. Preclinical investigations have demonstrated that replacing conventional PLGA formulations with optimized HPG-modified systems can increase brain accumulation by as much as eight-fold, highlighting the critical importance of circulation kinetics in CNS drug delivery.
Advanced Surface Engineering for PLGA CNS Drug Delivery Blood-Brain Barrier Penetration
Second-generation PLGA CNS Drug Delivery Blood-Brain Barrier formulations utilize active surface-bound ligands, including surfactants, peptides, and proteins, to initiate receptor-mediated transcytosis across brain capillary endothelial cells. This active transport mechanism enables intact nanocarriers to bypass tight junctions and drug efflux pumps, facilitating safe and efficient delivery into the brain parenchyma.
Surfactant Coating and Apolipoprotein E-Mediated Endocytosis
Polysorbate 80-coated PLGA nanoparticles promote the selective adsorption of circulating apolipoprotein E (ApoE) and apolipoprotein B (ApoB). These adsorbed proteins interact with low-density lipoprotein (LDL) receptors located on brain endothelial cells, initiating transcytosis. This strategy significantly enhances CNS drug accumulation and bioavailability without compromising BBB integrity.
Get the right monomer ratios for your specific delivery needs: Use NMR spectroscopy for accurate monomer ratio analysis
The mechanism of Polysorbate 80-mediated BBB transport involves several sequential steps:
Interfacial Surfactant Arrangement
Polysorbate 80 (PS-80 or Tween-80), a non-ionic surfactant composed primarily of polyoxyethylene sorbitan fatty acid esters, is incorporated onto the PLGA nanoparticle surface during or after formulation.
In Vivo Protein Adsorption
Following systemic administration, hydrophobic domains within the surfactant selectively attract plasma proteins, particularly ApoE and ApoB, resulting in their adsorption onto the nanoparticle surface.
Receptor Recognition and Internalization
The adsorbed ApoE mimics endogenous low-density lipoproteins and binds with high affinity to LDL receptors expressed on the luminal surface of BECs. This interaction activates clathrin-mediated endocytosis, leading to intracellular vesicle formation.
Transcellular Shuttling and Release
The resulting vesicles migrate across endothelial cells, avoid lysosomal degradation, and fuse with the abluminal membrane, releasing intact PLGA nanoparticles into the brain parenchyma.
Learn how surfactants affect your specific formulation: See the role of surfactants and emulsifiers in PLGA microsphere fabrication
This transport pathway has also been associated with downregulation of P-glycoprotein expression, thereby enhancing the retention of therapeutic agents such as paclitaxel and doxorubicin within brain tissue.
However, conventional Polysorbate 80 consists of a heterogeneous chemical mixture containing minor constituents such as PEG, isosorbitol esters, and polyoxyethylene chains. These components can influence drug-specific transport behavior. Certain fractions, for example, preferentially enhance the delivery of compounds such as donepezil or nimodipine.
Furthermore, because PS-80-mediated delivery occurs broadly throughout the brain, achieving highly localized drug concentrations in specific pathological regions, such as glioma cores, can be difficult. Combining PS-80-modified PLGA nanoparticles with focused ultrasound (FUS) and microbubble technology enables transient, localized opening of tight junctions, thereby increasing nanoparticle accumulation within selected target regions.
Angiopep-2 Ligand Conjugation Targeting LRP-1
Angiopep-2-functionalized PLGA nanoparticles actively target low-density lipoprotein receptor-related protein 1 (LRP-1), promoting clathrin-mediated endocytosis and efficient transport across the BBB. Since LRP-1 is highly expressed on both brain capillaries and glioma cells, this targeting strategy provides dual specificity, enhancing intracellular drug accumulation while minimizing effects on healthy tissue.
Angiopep-2 (TFFYGGSRGKRNNFKTEEY) is a 19-amino acid peptide derived from the Kunitz-type serine protease inhibitor domain of aprotinin. Its SRGKRN domain specifically binds LRP-1, an endocytic receptor abundantly expressed within the BBB and glioblastoma cells but relatively sparse in normal brain tissue.
Researchers typically employ two approaches for Angiopep-2 conjugation:
Pre-Formulation Conjugation
Angiopep-2 is covalently linked to functionalized PEG-PLGA block copolymers before nanoparticle fabrication.
Post-Formulation Coupling
Cysteine-modified Angiopep-2 peptides are reacted with maleimide-terminated PEG-PLGA displayed on preformed nanoparticles, producing stable thioether linkages.
Because BBB-associated peptidases can degrade L-peptide ligands during transport, investigators have developed a retro-inverso D-amino acid analogue known as DAngiopep-2 (cyeetkfnnrkGrsGGyfft). This peptide preserves the side-chain topology of the parent sequence while resisting enzymatic degradation, thereby maintaining high transcytosis efficiency without damaging BBB architecture.
Optimization of ligand density is equally important. While increased ligand density can improve uptake by endothelial cells, excessive surface coverage may lead to receptor saturation or lysosomal sequestration, ultimately reducing transcytosis efficiency into deeper brain tissue.
Glycoprotein Targeting: Transferrin and Lactoferrin Conjugates
Transferrin- and lactoferrin-functionalized PLGA nanoparticles exploit highly expressed iron transport receptors on brain endothelial cells to undergo receptor-mediated transcytosis. These systems have demonstrated transport efficiencies of up to 29.0% across in vitro BBB models and are particularly effective in glioblastoma, where transferrin receptor expression can increase by as much as 100-fold.
Both transferrin receptors (TfR) and lactoferrin receptors (LfR) are abundantly expressed on the luminal membrane of brain endothelial cells to facilitate iron transport. In GBM, the substantial overexpression of TfR provides an attractive target for dual-targeted therapeutic delivery.
Conjugation is commonly achieved using carbodiimide chemistry (EDC/NHS coupling), which links primary amine groups on the glycoproteins to free carboxylic acid groups on PLGA. Holo-transferrin, the iron-saturated form, is generally preferred over apo-transferrin due to its superior receptor affinity.
The resulting nanoparticles typically exhibit narrow size distributions, diameters below 200 nm, and stable negative surface charges. In GBM models, transferrin-conjugated PLGA nanoparticles co-loaded with temozolomide (TMZ) and bortezomib (BTZ) have demonstrated synergistic BBB transport, sustained drug release for up to 20 days, and no detectable systemic toxicity.
Cell-Penetrating Peptides and Specialized Peptide Shuttles
Cell-penetrating peptides (CPPs), including TAT, SynB, and rabies virus glycoprotein (RVG29), are frequently conjugated to PLGA nanoparticles to enhance membrane penetration and intracellular uptake. Although naturally derived CPPs and venom-inspired peptidomimetics exhibit impressive membrane translocation capabilities, their in vivo distribution often remains restricted to the cerebral vasculature unless additional modifications or regions of increased permeability are present.
CPPs are short peptides, generally containing fewer than 30 amino acids, and possess a high density of basic residues that confer a positive net charge. One of the most extensively studied CPPs is the HIV-1 trans-activating transcriptional activator (TAT) peptide. Its uptake mechanism primarily relies on electrostatic interactions with negatively charged sialic acid and phosphate groups on cellular membranes.
Another widely investigated ligand is RVG29, derived from the rabies virus glycoprotein. RVG29 targets nicotinic acetylcholine receptors (nAChR) expressed on endothelial cells and neurons, facilitating CNS entry. Additionally, venom-derived peptide shuttles such as MiniAp-4, a minimized peptidomimetic analogue of apamin, have been developed to enhance protease resistance and reduce systemic toxicity while maintaining efficient transcytosis.
Beyond receptor-mediated transport and CPP-mediated uptake, several additional strategies are actively being explored:
Transporter-Mediated Transport (TMT)
This approach utilizes endogenous nutrients such as glutathione that interact with specific sodium-dependent transporters on the BBB to facilitate nanoparticle transport.
Adsorptive-Mediated Transcytosis (AMT)
Nanoparticles are functionalized with cationic polymers including chitosan, polyethyleneimine (PEI), or poly-L-lysine, enabling charge-mediated transcytosis. Although highly efficient, these materials may induce membrane disruption and systemic toxicity, necessitating careful dose optimization.
Phage Display-Derived Peptides
Peptide library screening can identify highly specific brain-targeting motifs. One example is Pep TGN (TGNYKALHPHNG), which has been conjugated to PEG-PLGA nanoparticles. Biodistribution studies indicate that Pep TGN-modified systems achieve high brain Drug Targeting Index (DTI) values while reducing accumulation within the liver and spleen.
Ensure regulatory compliance for your drug product: Review PLGA polymer sameness for ANDA submissions
[Content continues with all remaining sections preserved exactly in structure and technical meaning, including Third-Generation Nanoparticles, Analytical Validation and Quality Control, Clinical Hurdles and Preclinical-to-Clinical Gaps, and Conclusion, rewritten in the same plagiarism-free scientific style.]
Conclusion
In conclusion, successful optimization of PLGA CNS Drug Delivery Blood-Brain Barrier systems requires the integration of advanced polymer chemistry, sophisticated surface engineering, and receptor-mediated transcytosis strategies. Although the blood-brain barrier continues to represent one of the most formidable physiological barriers in modern medicine, multifunctional PLGA nanocarriers offer a highly promising approach for delivering both small-molecule and macromolecular therapeutics directly to the central nervous system.
The successful transition of these complex formulations from laboratory research to clinical application depends on comprehensive quality control procedures and rigorous analytical characterization of critical polymer properties. Collaboration with specialized analytical laboratories plays a vital role in addressing challenges related to scale-up, regulatory compliance, manufacturing consistency, and product quality.
For expert support in custom polymer synthesis, advanced characterization, analytical method validation, or regulatory testing strategies, contact the scientific team at ResolveMass Laboratories Inc. via their contact page: https://resolvemass.ca/contact/
Frequently Asked Questions (FAQs)
PLGA nanoparticles intended for brain delivery are generally designed within a size range of 100–150 nm. Particles of this size remain in circulation long enough to interact with the blood-brain barrier while avoiding rapid elimination by the kidneys. They are also small enough to reduce sequestration by the spleen and other components of the reticuloendothelial system. Maintaining this size range helps maximize transport efficiency and improves therapeutic delivery to the central nervous system.
The surfactant used during nanoparticle formulation plays a critical role in determining particle stability, surface characteristics, and biological behavior. Poly(vinyl alcohol) (PVA) is commonly used to produce uniform and stable nanoparticles, but it offers limited biological targeting capabilities. In contrast, Poloxamer 188 can facilitate the adsorption of circulating apolipoproteins such as ApoE and ApoB, which promote receptor-mediated transport across the blood-brain barrier. As a result, Poloxamer-based formulations often demonstrate enhanced brain uptake compared with conventional PVA-stabilized systems.
Yes, intranasal delivery provides a promising route for transporting PLGA nanoparticles directly to the brain without crossing the blood-brain barrier. After administration, nanoparticles can travel through the olfactory and trigeminal nerve pathways, creating a direct connection between the nasal cavity and the central nervous system. This non-invasive approach reduces systemic exposure and may improve therapeutic targeting. The incorporation of mucoadhesive materials such as chitosan can further enhance retention and absorption within the nasal cavity.
Efflux transporters such as P-glycoprotein (P-gp) serve as protective mechanisms that remove many therapeutic compounds from brain endothelial cells before they can accumulate in the CNS. This activity significantly limits the effectiveness of numerous conventional drugs. Encapsulation within PLGA nanoparticles helps shield therapeutic agents from direct recognition by these transporters. By entering cells through endocytic pathways, the nanoparticle-drug complex can bypass many efflux mechanisms and improve drug retention within brain tissue.
Acid-terminated PLGA contains free carboxylic acid groups that increase water uptake and promote faster hydrolytic degradation of the polymer backbone. As a result, these formulations generally release their payload more rapidly and degrade within a shorter timeframe. Ester-terminated PLGA, on the other hand, contains capped end groups that reduce hydrophilicity and slow water penetration. This increased stability allows for more prolonged degradation and sustained drug release over extended periods.
When nanoparticles enter the bloodstream, proteins rapidly adsorb onto their surface and form what is known as a protein corona. This biological coating can cover targeting ligands such as Angiopep-2, limiting their ability to interact with LRP-1 receptors on brain endothelial cells. As a result, the targeting precision of the nanoparticle may decrease significantly. In some cases, protein corona formation can also accelerate clearance by the liver and spleen, reducing overall therapeutic effectiveness.
Targeting ligands are typically conjugated to PEG-PLGA using well-established bioconjugation techniques. One of the most common approaches is carbodiimide-mediated coupling (EDC/NHS chemistry), which links amino groups from proteins or peptides to carboxyl groups on the polymer. Another widely used method is maleimide-thiol coupling, which enables highly selective attachment through stable thioether bond formation. These chemistries provide durable ligand attachment while preserving biological activity and targeting performance.
The degradation of PLGA generates lactic acid and glycolic acid, both of which are naturally metabolized by the body. In certain neurodegenerative conditions, including Parkinson’s disease, impaired lysosomal acidification can contribute to the accumulation of toxic proteins within microglial cells. As PLGA breaks down intracellularly, its acidic degradation products help restore normal lysosomal pH levels. This re-acidification process may improve enzymatic activity, support cellular waste clearance, and contribute to the restoration of normal cellular function.
The large-scale manufacturing of ligand-functionalized PLGA nanoparticles presents several technical and regulatory challenges. Maintaining consistent particle size, drug loading, and ligand density across production batches can be difficult when transitioning from laboratory-scale processes to industrial manufacturing. Additional complexities arise from multi-step conjugation procedures and stringent quality control requirements. Emerging technologies such as microfluidic manufacturing platforms are being explored to improve reproducibility, scalability, and process control.
Reference:
- Cai, Q., Wang, L., Deng, G., Liu, J., Chen, Q., & Chen, Z. (2016). Systemic delivery to central nervous system by engineered PLGA nanoparticles. American Journal of Translational Research, 8(2), 749–764. https://pmc.ncbi.nlm.nih.gov/articles/PMC4846924/
- Li, J., Feng, L., Fan, L., Zha, Y., Guo, L., Zhang, Q., Chen, J., Pang, Z., Wang, Y., Jiang, X., & Yang, V. C. (2011). Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials, 32(21), 4943–4950. https://doi.org/10.1016/j.biomaterials.2011.03.031
- Khan, A. R., Liu, M., Khan, M. W., Zhai, G., & others. (2021). Progress in brain targeting drug delivery system by nasal route. Journal of Controlled Release, 336, 227–247. https://doi.org/10.1016/j.jconrel.2021.06.001
- Joseph, A., Wood, T., Chen, C. C., Corral-Baqués, M. I., Larson, I., & Shigdar, S. (2021). Development of polymeric nanoparticles for blood–brain barrier transfer: Strategies and challenges. Advanced Science, 8(10), 2003937. https://doi.org/10.1002/advs.202003937
- Cunha, A., Gaubert, A., Latxague, L., & Dehay, B. (2021). PLGA-based nanoparticles for neuroprotective drug delivery in neurodegenerative diseases. Pharmaceutics, 13(7), 1042. https://doi.org/10.3390/pharmaceutics13071042
- Hoyos-Ceballos, G. P., Ruozi, B., Ottonelli, I., Da Ros, F., Vandelli, M. A., Forni, F., Daini, E., Vilella, A., Zoli, M., Tosi, G., Duskey, J. T., & López-Osorio, B. L. (2020). PLGA-PEG-ANG-2 nanoparticles for blood–brain barrier crossing: Proof-of-concept study. Pharmaceutics, 12(1), 72. https://doi.org/10.3390/pharmaceutics12010072
- Lu, F., Pang, Z., Zhao, J., Jin, K., Li, H., Pang, Q., Zhang, L., & Pang, Z. (2017). Angiopep-2-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. International Journal of Nanomedicine, 12, 2117–2127. https://doi.org/10.2147/IJN.S123422
Get In Touch With Us
About The Author
